ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

Launched by ALNYLAM PHARMACEUTICALS · Sep 18, 2020

Keywords

ClinConnect Summary

The ConTTRibute study is a global research project aimed at understanding more about a condition called transthyretin-mediated amyloidosis (ATTR amyloidosis). This study will look at how common this condition is, how it affects people's health over time, and how it is managed in everyday medical practice. Researchers are particularly interested in how well two treatments, patisiran and vutrisiran, work and how safe they are when used by doctors in the real world. The study will also explore how the disease develops in people who carry a gene that could cause ATTR amyloidosis but may not show symptoms yet.

To participate in this study, individuals must have a diagnosis of ATTR amyloidosis or have a known genetic variant that can lead to the disease. In Germany, participants must also be receiving approved treatments as outlined in the product information. However, people who are currently involved in another clinical trial cannot join this study. Participants can expect to share their health information and experiences related to the disease, helping researchers gather valuable insights that could improve care for others in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of ATTR amyloidosis or documented known disease-causing TTR variant for the cohort of pre-symptomatic carriers
• • Germany Only: Patients must be treated per the summary of product characteristics (SmPC) for any approved treatment for ATTR amyloidosis
• Exclusion Criteria:
• • Current enrollment in a clinical trial for any investigational agent